Dasabuvir and Ombitasvir / Paritaprevir / Ritonavir (Addendum to Commissions A15-03 and A15-04) [Internet].

On 11 June 2015, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to conduct a supplementary assessment for the commissions A15-03 (Dasabuvir – Benefit assessment according to §35a Social Code Book V) and A15-04 (Ombitasvir / paritaprevir / ritonavir – Benefit assessment according to §35a Social Code Book V).

http://ift.tt/2rvdxX4